Breakthrough in Pediatric Cancer Immunotherapy from Swiss Research Team
Researchers at the University of Bern and affiliated institutions have developed optimized L1CAM-CAR T cells that demonstrate enhanced activity against rhabdomyosarcoma models expressing moderate levels of the target antigen. This advancement addresses a key limitation in chimeric antigen receptor T cell therapies for solid tumors, where antigen density often falls below the threshold needed for effective tumor cell killing.
The work, led by a team including Caroline Piccand, Corentin Gauthier, Pascal Klöckner, Sara G. Danielli, Christian Vokuhl, Valerie Haesler, Andreina Schöberlein, Sarah Brüningk, Rhoikos Furtwängler, Jochen Rössler, Andrea Timpanaro, and Michele Bernasconi, appears in the journal Cancer Letters. The full publication is available at https://www.sciencedirect.com/science/article/pii/S0304383526004556.
Understanding Rhabdomyosarcoma and Current Treatment Challenges
Rhabdomyosarcoma represents the most common soft tissue sarcoma in children and adolescents. It originates from primitive skeletal muscle progenitor cells and divides into embryonal and alveolar subtypes, with molecular classification further distinguishing fusion-positive cases that carry particularly poor prognoses in relapsed or metastatic settings. Standard multimodal treatments including chemotherapy, surgery, and radiation have improved outcomes for many patients, yet survival rates for those with advanced alveolar disease remain below 30 percent in many cohorts.
Immunotherapies such as CAR T cells have transformed outcomes in blood cancers and are now being refined for solid tumors like rhabdomyosarcoma. The challenge lies in identifying tumor-selective antigens expressed at sufficient density while avoiding toxicity to healthy tissues. Antigens such as HER2, B7-H3, and FGFR4 have undergone preclinical and early clinical evaluation, with some promising signals but inconsistent results at lower expression levels.
L1CAM as a Therapeutic Target in Rhabdomyosarcoma
L1 cell adhesion molecule, or L1CAM, is a transmembrane glycoprotein involved in neural development and cell migration. Profiling across cell lines, patient-derived xenografts, and clinical samples revealed consistent moderate expression in rhabdomyosarcoma, particularly in alveolar subtypes, with minimal presence in healthy tissues. This expression pattern positions L1CAM as a rational target that balances efficacy potential with a favorable safety profile.
Earlier studies had validated L1CAM in other pediatric cancers, including a completed phase I trial in neuroblastoma that confirmed tolerability and tumor trafficking without objective responses. The current research extends this foundation to rhabdomyosarcoma, where moderate antigen density had previously limited CAR T cell potency.
Engineering and Testing Optimized CAR Constructs
The team engineered multiple L1CAM-directed CAR variants using the single-chain variable fragment from the CE7 antibody. Variations in hinge length and costimulatory domains were systematically compared. The construct designated L1CAM.III, featuring a long hinge and CD28 costimulatory domain, emerged as superior in vitro, producing the strongest cytotoxicity and interferon-gamma release against rhabdomyosarcoma cell lines.
Orthotopic mouse models of rhabdomyosarcoma provided the critical in vivo test bed. L1CAM.III-CAR T cells achieved tumor regression, extended survival, and demonstrated persistence. Performance was notably stronger against alveolar models, and no off-tumor toxicity was observed. These results compared favorably to reference constructs targeting B7-H3 while offering an improved safety margin.
Photo by Michael Marsh on Unsplash
Institutions Driving the Research
The collaborative effort draws primarily from the Department of Pediatric Hematology and Oncology at Inselspital, Bern University Hospital, and the Translational Cancer Research group at the University of Bern’s Department for BioMedical Research. Additional contributions came from the University Children’s Hospital of Zurich and the Ben Towne Center for Childhood Cancer and Blood Disorders Research at Seattle Children’s Research Institute. This international network underscores the global nature of pediatric oncology research and the value of cross-institutional data sharing and model development.
Such university-based programs play a central role in training the next generation of researchers and clinicians. Graduate students and postdoctoral fellows at these centers gain hands-on experience in CAR engineering, preclinical modeling, and translational workflows that directly inform career pathways in academic medicine and biotechnology.
Implications for Broader CAR T Optimization Strategies
The findings highlight how hinge and costimulatory domain choices can overcome the barrier of low-to-moderate antigen density. CD28-based signaling provided stronger early activation, which proved advantageous in this setting. These design principles may extend to other solid tumor targets where antigen levels vary across patients or within heterogeneous tumors.
Clinical translation will require further safety studies and combination approaches, potentially with checkpoint inhibitors or other modalities already under investigation in sarcoma trials. The absence of off-tumor activity in the models supports continued exploration of L1CAM as a standalone or dual-targeted approach.
Perspectives from the Research Community
Experts in pediatric oncology note that antigen density optimization represents one of the most pressing engineering challenges in the field. The Bern-led work provides concrete evidence that rational CAR design can expand the therapeutic window for targets previously considered marginal. This aligns with ongoing efforts at major centers to refine constructs for FGFR4 and other antigens in dedicated rhabdomyosarcoma trials.
University administrators and research directors emphasize the importance of sustained funding for preclinical infrastructure, including patient-derived models and advanced imaging, that enabled the detailed characterization reported here. Such investments directly support the academic mission of discovery and workforce development.
Future Outlook and Opportunities in Cancer Research
As these optimized L1CAM-CAR T cells move toward clinical evaluation, they open new avenues for academic researchers interested in immunotherapy, pediatric sarcomas, and translational bioengineering. Postdoctoral positions and faculty roles in departments of pediatric oncology, immunology, and biomedical engineering are likely to expand as institutions seek expertise in CAR optimization and solid tumor modeling.
The study also reinforces the value of preprint servers and rapid publication pathways that allow findings like these to reach the community quickly, accelerating follow-on research worldwide.
Photo by Erika Fletcher on Unsplash
Resources for Researchers and Job Seekers
Professionals exploring opportunities in this dynamic area can review current openings in higher education research roles. Academic institutions continue to recruit for positions that advance precisely this type of work, from laboratory scientists to clinical trial coordinators.